Transgenic Expression of Laminin α1 Chain Does Not Prevent Muscle Disease in the mdx Mouse Model for Duchenne Muscular Dystrophy
- 30 April 2011
- journal article
- research article
- Published by Elsevier BV in The American Journal of Pathology
- Vol. 178 (4), 1728-1737
- https://doi.org/10.1016/j.ajpath.2010.12.030
Abstract
No abstract availableKeywords
Funding Information
- Muscular Dystrophy Association
- Anna-Greta Crafoord Foundation for Rheumatological Research
- Swedish National Research Council
- Alfred Österlund Foundation
This publication has 37 references indexed in Scilit:
- Laminin-111: A Potential Therapeutic Agent for Duchenne Muscular DystrophyMolecular Therapy, 2010
- Distinct Roles for Laminin Globular Domains in Laminin α1 Chain Mediated Rescue of Murine Laminin α2 Chain DeficiencyPLOS ONE, 2010
- Laminin-111 protein therapy prevents muscle disease in the mdx mouse model for Duchenne muscular dystrophyProceedings of the National Academy of Sciences of the United States of America, 2009
- Dystroglycan: a possible mediator for reducing congenital muscular dystrophy?Trends in Biotechnology, 2007
- Laminin α1 chain improves laminin α2 chain deficient peripheral neuropathyHuman Molecular Genetics, 2006
- Laminin α1 chain mediated reduction of laminin α2 chain deficient muscular dystrophy involves integrin α7β1 and dystroglycanFEBS Letters, 2006
- Absence of α7 integrin in dystrophin-deficient mice causes a myopathy similar to Duchenne muscular dystrophyHuman Molecular Genetics, 2006
- Laminin 1 chain reduces muscular dystrophy in laminin 2 chain deficient miceHuman Molecular Genetics, 2004
- Alternative Splice Variants of α7β1Integrin Selectively Recognize Different Laminin IsoformsJournal of Biological Chemistry, 2002
- Serum CK, calcium, magnesium, and oxidative phosphorylation in mdx mouse muscular dystrophyMuscle & Nerve, 1988